Compare Honeywell International Inc (HON) vs Sana Biotechnology Inc (SANA) Price & Performance

Honeywell International IncTrade

Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Honeywell International Inc vs Sana Biotechnology Inc — how do they compare? Honeywell International Inc trades at $229.27 (market cap $71.66B), while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Honeywell International Inc is far larger — about 82× Sana Biotechnology Inc's market cap, and Honeywell International Inc pays a 4.21% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

	HON	SANA
Market Cap	$71.66B	$873.84M
Sector	Industrials	Health
52-Week High	$248.04	$5.92
52-Week Low	$188.14	$2.68
Enterprise Value	$96.01B	$848.03M
Dividend Yield	4.21%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

HON

Jim Cramer advises shifting from volatile AI stocks to stable, high-quality companies outside tech for now.CNBC · 1 day agoBullish Honeywell Aerospace to release Q2 earnings on August 5 with a conference call at 5 pm EDT.PRNewsWire · 4 days agoNeutral View details →

SANA

View details →

About Honeywell International Inc

Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.